Reimagining Precision Medicine: What the Next Era Will Look Like
Session details:
For more than a decade, “precision medicine” has largely meant applying genomic insights to tailor treatments most visibly in oncology. But the landscape is shifting. Breakthroughs in CRISPR gene editing, mRNA platforms, multimodal diagnostics, and AI‑driven biological discovery are rapidly paving the way for Precision Medicine 2.0: a more intentional, mechanistic, and individualized model of care.
This panel brings together leaders across pharma, diagnostics, data science, and clinical practice to explore how these shifts will transform drug development and patient care. We’ll examine the technologies enabling this new era from next‑gen gene editing and programmable mRNA medicines to AI systems that can recognize patterns no human can see and discuss what it will take to knit these capabilities into a cohesive and clinically actionable precision‑care ecosystem.
Key Discussion Themes
- Precision Medicine 2.0: How CRISPR, mRNA, and AI are reshaping research and clinical care
- Regulatory shifts: Implications of the FDA’s “plausible mechanism” pathway for rare and genetic diseases
- Redefining disease: Moving from broad diagnoses to biology-driven segmentation
- Enabling technologies: AI, multiomics, programmable therapeutics, digital biomarkers, and natural history data
- Building the ecosystem: Integrating pharma, diagnostics, data platforms, and regulatory frameworks
- The physician’s role: Using rapid diagnostics and biomarker-guided decisions to personalize care
